The Food and Drug Administration (FDA) has cleared a 3-minute session protocol, Theta Burst Stimulation, for the NBT System (Nexstim) used to treat major depressive disorder (MDD). Previously, the standard protocol time for the therapy was 37 minutes.
Prenatal exposure to ambient pesticides within 2000m of maternal residence during pregnancy is associated with an increased risk for autism spectrum disorder.
A recent study published in the New England Journal of Medicine assessed the risk of new-onset psychosis among adolescents and young adults with attention deficit hyperactivity disorder (ADHD) initiated on various stimulant medications.
The Food and Drug Administration (FDA) has approved Zulresso (brexanolone; Sage Therapeutics) injection for the treatment of postpartum depression in adult women, the first drug to be approved for this indication. Zulresso, an analogue of the endogenous human hormone allopregnanolone, is intended for continuous intravenous (IV) infusion over 2.5 days following a titration schedule. It…
An analysis of data from over 3.5 million patients found comparable clinical outcomes among patients who initiated generics vs those who were treated with brand-name drugs for chronic conditions such as diabetes, hypertension, osteoporosis, depression and anxiety.
Tied to improvements in pain, anxiety, depression among breast cancer survivors with fatigue
Clinical studies evaluating the safety, efficacy and tolerability of rapastinel as an adjunctive treatment for major depressive disorder (MDD) did not meet primary and key secondary endpoints, according to topline results announced by Allergan.
The Food and Drug Administration (FDA) has approved Spravato (esketamine nasal spray; Janssen) for the treatment of adult patients with treatment-resistant depression (TRD), in conjunction with an oral antidepressant.
When managing patients with depression, clinicians must always be cognizant that suicide is a possibility, and that sometimes the medications prescribed can actually exacerbate the situation.
No increased risk observed after MMR in those with sibling autism history, autism risk factors
